Entitlement Offer Cleansing Statement
Released
Released
Announcement PDF
ABN 16 165 160 841
ASX RELEASE
16 April 2024
Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth)
This notice is given by Amplia Therapeutics Limited (ASX: ATX) ACN 165 160 841 (Amplia or the
Company) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (Act).
Amplia has announced a pro rata, non-accelerated, non-renounceable entitlement offer (Entitlement
Offer) of two fully paid Amplia ordinary shares (Shares) for every five Shares held by eligible Amplia
shareholders with a registered address in Australia or New Zealand (or as otherwise determined by
the Company) as at 7.00pm (Adelaide time) on Friday, 19 April 2024.
The Entitlement Offer is being conducted at an issue price of $0.055 per Share (Offer Price) to raise
approximately $4.27 million (before costs). A total of approximately 77,602,558 Shares will be issued
under the Entitlement Offer.
The Entitlement Offer is being lead managed and fully underwritten by Taylor Collison Limited ACN
008 172 450 (Lead Manager).
Amplia gives notice that:
1. the Shares to be issued pursuant to the Entitlement Offer will be offered for issue without
disclosure under Part 6D.2 of the Act;
2. this notice is being given under section 708AA(2)(f) of the Act;
3. as at the date of this notice Amplia has complied with:
a. the provisions of Chapter 2M of the Act as they apply to Amplia; and
b. sections 674 and 674A of the Act;
4. as at the date of this notice, there is no excluded information of the type referred to in sections
708AA(8) and 708AA(9) of the Act that is required to be set out in this notice under section
708AA(7)(d) of the Act; and
5. under the Entitlement Offer, the Company will offer approximately 77,602,558 Shares, which, if
the maximum number of Shares is issued (noting that the Entitlement Offer is fully underwritten),
would result in the total Share capital of the Company upon the completion of the Entitlement
Offer increasing to up to approximately 271,608,342 Shares. A summary of the potential control
impacts of the Entitlement Offer on Amplia is set out below.
Effect on the control of Amplia
The potential effect that the issue of the new Shares will have on the control of the Company, and the
consequences of that effect, will depend on a number of factors, including investor demand, the take
up of new Shares under the Entitlement Offer, the level of discount of Shares offered under the
Entitlement Offer and the underwriting and sub-underwriting arrangements entered into by the
Company and the Lead Manager.
Given the structure of the Entitlement Offer as a fully underwritten, ‘two-for-five’ pro-rata issue where
shareholders are permitted to subscribe for additional Shares in excess of their entitlement up to an
additional 100% of their Entitlement, the likely effect that the issue of the new Shares will have on the
control of the Company can be summarised as follows:
(a)
(b)
if all eligible shareholders take up their entitlement for the new Shares under the Entitlement
Offer, the Entitlement Offer will have no material effect on the control of the Company;
to the extent that any eligible shareholder:
Level 17, 350 Queen Street, Melbourne VIC 3000
Email info@ampliatx.com
www.ampliatx.com
takes up their entitlement for new Shares under the Entitlement Offer and applies for
additional new Shares, that eligible shareholder’s percentage holding in the Company will
increase;
• does not take up their entitlement for new Shares under the Entitlement Offer, that eligible
shareholder’s percentage holding in the Company will be diluted;
to the extent that there are any shortfall Shares following completion of the Entitlement Offer,
the Underwriter (and sub-underwriters) will acquire those new Shares pursuant to the
underwriting arrangements discussed below.
•
(c)
Ineligible shareholders (being those shareholders with a registered address outside Australia and
New Zealand, or as otherwise determined by the Company) will not be able to subscribe for Shares
and will have their percentage shareholding in the Company diluted.
Underwriting and sub-underwriting arrangements
The Entitlement Offer is fully underwritten by the Lead Manager pursuant to an underwriting
agreement entered into between the Lead Manager and the Company dated 16 April 2024. The Lead
Manager is not a related party of the Company for the purposes of the ASX Listing Rules and
Corporations Act and has no current holding in the Company’s Shares at the date of this Notice.
The Company understands that the Lead Manager has entered into sub-underwriting commitments in
respect of its obligations to underwrite the Entitlement Offer. One of the sub-underwriters is a related
party, being Dr Robert Peach.
Given the fact that the Entitlement Offer is fully underwritten, and taking into account the ‘two-for-five’
offer ratio, the shortfall facility where shareholders are permitted to subscribe for an uncapped number
of Shares in excess of their entitlement and the sub-underwriting commitments obtained from certain
institutional investors, no person is expected to hold more than 19.9% of the Company’s issued
Shares on completion of the Entitlement Offer.
This ASX announcement was approved and authorised for release by the Board of Amplia
Therapeutics.
- End For Further Information
Dr Chris Burns
CEO and Managing Director
chris@ampliatx.com
www.ampliatx.com
About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal
Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in
cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and
ovarian cancers. FAK also plays a significant role in a number of chronic diseases, such as idiopathic
pulmonary fibrosis (IPF) and the Company is also developing its FAK inhibitors in these indications.
IMPORTANT INFORMATION
This announcement has been prepared for publication in Australia and may not be released to U.S.
wire services or distributed in the United States. This announcement does not constitute an offer to
sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any
securities described in this announcement have not been, and will not be, registered under the U.S.
Securities Act of 1933 and may not be offered or sold in the United States except in transactions
exempt from, or not subject to, registration under the U.S. Securities Act and applicable U.S. state
securities laws.
Share your feedback
Discover